title: Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study.
abstract: This prospective study compared the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and cisplatin with the standard therapy of cyclophosphamide/cisplatin in women with suboptimal stage III and stage IV ovarian cancer. Of the initial 410 women who presented with advanced disease and greater than 1 cm residual masses after initial surgery, 386 met all eligibility criteria and were randomly assigned to receive a regimen of cisplatin 75 mg/m2 and cyclophosphamide 750 mg/m2 or cisplatin 75 mg/m2 and paclitaxel 135 mg/m2 delivered over 24 hours. Dosage reductions were permitted in the event of significant toxicity. Among 216 patients with measurable disease, responses were reported in 73% of those receiving cisplatin/paclitaxel and in 60% of those receiving cisplatin/cyclophosphamide. Median progression-free survival was significantly longer (P < .001) in the group treated with cisplatin/paclitaxel, compared with those receiving cisplatin/cyclophosphamide (17.9 v 12.9 months, respectively).
authors.affiliation: Department of Medicine, Emory University, Atlanta, GA, USA.
authors.forename: W P
authors.initials: WP
authors.lastname: McGuire
authors.forename: W J
authors.initials: WJ
authors.lastname: Hoskins
authors.forename: M F
authors.initials: MF
authors.lastname: Brady
authors.forename: P R
authors.initials: PR
authors.lastname: Kucera
authors.forename: E E
authors.initials: EE
authors.lastname: Partridge
authors.forename: K Y
authors.initials: KY
authors.lastname: Look
authors.forename: D L
authors.initials: DL
authors.lastname: Clarke-Pearson
authors.forename: M
authors.initials: M
authors.lastname: Davidson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage*; D011446:Prospective Studies
chemical_list: D003520:Cyclophosphamide; D017239:Paclitaxel; D002945:Cisplatin